Trending Topics in Gastroenterology | GastroAGI

Early-Onset Disease Is Reshaping the Global Burden of Colorectal Cancer | Nature Reviews Clinical Oncology

Introduction Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although CRC has historically been concentrated in Western high-income countries, its global epidemiology is rapidly changing, with rising incidence now extending across diverse geographic and socioeconomic settings. Problem Statement The global rise in CRC is increasingly driven by early-onset disease, particularly in individuals younger than 50 years, challenging traditional assumptions that CRC is predominantly a disease of older adults in high-income populations. This shift cannot be fully explained by inherited susceptibility or expanded screening alone, suggesting that evolving environmental, metabolic and lifestyle exposures are playing a major role in reshaping CRC risk worldwide. Summary This review highlights a major epidemiologic transition in CRC, with disease burden increasingly shifting beyond Western high-income countries and disproportionately affecting younger populations. The rise in early-onset CRC, first recognized in the 1990s, is now a global phenomenon and appears to reflect a birth-cohort effect implicating shared generational exposures rather than screening patterns alone. The authors emphasize that while hereditary risk remains important, emerging global CRC trends are more likely driven by non-genetic factors, including Westernized dietary patterns, sedentary lifestyle, obesity, gut microbial disruption and increasing exposure to environmental contaminants associated with rapid urbanization. These exposures may contribute not only to carcinogenesis but also to the distinct biology of early-onset CRC. The review further underscores the potential of integrating genomic, epigenomic and microbiome profiling to better define disease mechanisms and support earlier detection and precision prevention. Importantly, the authors highlight a major evidence gap in low- and middle-income regions, where under-representation in molecular and epidemiologic studies risks widening disparities in CRC prevention and control. This review positions early-onset CRC as a defining global oncology challenge requiring both biologic and public health recalibration.

Temab-A in Refractory Colorectal Cancer: JCO | May 2026

Introduction Treatment options for metastatic colorectal cancer (mCRC) in late-line settings remain limited, particularly in patients with microsatellite stable disease. Antibody-drug conjugates (ADCs) targeting tumour-specific pathways represent an emerging strategy to improve outcomes. Temab-A (ABBV-400), a c-Met–targeting ADC linked to a topoisomerase-1 inhibitor payload, is designed to deliver cytotoxic therapy directly to tumour cells. Problem Statement Patients with heavily pretreated mCRC often have a poor prognosis and limited therapeutic options. While targeted therapies and immunotherapy have transformed some subsets, microsatellite-stable, BRAF wild-type mCRC remains a major unmet need. The challenge is to identify treatments that provide meaningful responses with acceptable toxicity. Summary This phase I study evaluated Temab-A in advanced solid tumours, with a focus on mCRC. The maximum tolerated dose was established at 3.0 mg/kg, with 2.4 mg/kg every 3 weeks identified as the optimal dose based on safety and activity. Across 122 patients with mCRC, Temab-A demonstrated promising antitumor activity, with an overall response rate of 15.6% and a disease control rate of nearly 75%. Median progression-free survival was 4.6 months, and overall survival reached 10.4 months, suggesting a clinically meaningful benefit in a refractory population. Toxicities were common but manageable, predominantly gastrointestinal and hematologic. Treatment discontinuation and mortality rates were relatively low. Overall, Temab-A shows encouraging early efficacy as a targeted ADC in late-line mCRC, warranting further evaluation in phase II trials and combination strategies.

Biology-Driven Scoring Is Redefining Risk Stratification in Colorectal Liver Metastases: ESMO Open

Introduction Colorectal liver metastases (CRLM) remain a major determinant of mortality in colorectal cancer, with hepatic resection offering the best chance of long-term survival in selected patients. However, outcomes after surgery remain highly variable, and recurrence is common, highlighting the need for more precise tools to guide treatment selection and timing beyond conventional clinicopathologic assessment. Problem Statement Traditional clinical risk scores for CRLM, although widely used in surgical decision making, are limited by their reliance on static anatomical and morphological variables. These models inadequately capture tumor biology, treatment sensitivity and real-time disease evolution, restricting their ability to predict recurrence, guide systemic therapy or support precision treatment strategies in modern multidisciplinary care. Summary This review outlines the transition from conventional anatomy-based risk scoring toward a more dynamic and biologically informed framework for CRLM management. Classical clinical risk scores remain useful for baseline prognostication, but their predictive value is increasingly constrained in the era of molecular oncology. Emerging biomarkers—including tumor genomics, histological growth patterns and circulating tumor DNA (ctDNA)—provide clinically relevant insight into tumor behavior, metastatic biology and residual disease. Molecular alterations such as RAS, BRAF and mismatch repair status refine prognosis and increasingly influence treatment strategy, particularly with the expansion of targeted therapies and immunotherapy. Histological growth patterns offer additional prognostic value by distinguishing biologically favorable from aggressive liver metastatic phenotypes, while ctDNA has emerged as one of the most promising dynamic biomarkers for real-time monitoring of recurrence risk, treatment response and minimal residual disease after resection. The authors propose that integrating static clinical variables with dynamic molecular and liquid biopsy data can enable adaptive risk stratification across the treatment continuum. This biology-driven approach represents a major step toward precision oncology in CRLM, with the potential to improve patient selection, optimize perioperative therapy and better align surgery with tumor biology.

Standardizing Trial Endpoints for Oligometastatic Cancer Therapy: The Lancet Oncology

Introduction Oligometastatic cancer represents an intermediate disease state characterized by limited metastatic burden and a potentially distinct therapeutic window for metastases-directed therapy (MDT). As MDT becomes increasingly integrated into oncologic care, defining meaningful and consistent clinical trial endpoints has become essential to accurately assess treatment benefit and guide future therapeutic strategies. Problem Statement Clinical trials evaluating MDT in oligometastatic cancer have used highly variable primary endpoints, limiting cross-trial comparability and complicating interpretation of clinical benefit. Traditional endpoints such as overall survival and progression-free survival remain widely used, but they may not fully capture the unique therapeutic intent of MDT, particularly in settings where repeat local therapy can delay systemic progression without constituting treatment failure. Summary This review and Delphi consensus from the EORTC–ESTRO OligoCare consortium proposes a standardized framework for primary endpoints in clinical trials of MDT for oligometastatic cancer. Based on a systematic review of 121 comparative trials and a structured international consensus process involving experts and patient representatives, overall survival emerged as the preferred primary endpoint, reflecting its enduring clinical relevance. However, the panel emphasized that overall survival alone may not adequately capture the distinct benefits of MDT. In addition to progression-free survival, two alternative endpoints reached strong consensus: polymetastatic progression-free survival and systemic therapy-free survival. These endpoints are particularly valuable in MDT-based strategies because they allow repeat local interventions without prematurely defining treatment failure and better reflect the goal of delaying widespread progression or escalation of systemic treatment. Patient representatives also identified preservation of quality of life, particularly time to quality-of-life deterioration, as a major priority. This consensus provides a more clinically meaningful and patient-centered framework for future MDT trials and is expected to improve study design, comparability and translational relevance across oligometastatic oncology.

PancreaSure in Early PDAC: Gastroenterology | May 2026

Introduction Early detection of pancreatic ductal adenocarcinoma (PDAC) remains one of the most critical unmet needs in gastroenterology. Multibiomarker panels like PancreaSure represent an important step toward improving early diagnosis beyond traditional markers such as CA19-9. Initial validation studies have shown encouraging diagnostic performance, particularly in asymptomatic high-risk populations. Problem Statement Despite strong initial results, the key challenge is real-world applicability. Biomarkers that perform well in controlled cohorts often lose specificity in symptomatic and heterogeneous clinical populations. Additionally, lack of organ specificity raises concerns about whether a positive result truly reflects pancreatic cancer or a broader malignancy signal. Summary This commentary highlights important limitations of PancreaSure that may impact its clinical adoption. While specificity was high in asymptomatic high-risk individuals, it declined significantly in symptomatic patients, performing worse than CA19-9. This reduction may be due to common benign conditions such as pancreatic cysts and new-onset diabetes, which can generate false-positive signals. Another major concern is the lack of organ specificity. Several components of the biomarker panel are elevated in multiple malignancies, making it unclear whether a positive test reflects PDAC or other cancers. This creates a clinical dilemma, particularly when imaging is negative. The authors also emphasise the need for subgroup analyses, especially in patients with low or absent CA19-9 expression, where multibiomarker panels may offer added value. Overall, PancreaSure is a promising tool, but requires further validation in real-world populations, better calibration in symptomatic cohorts, and clearer interpretation strategies before routine clinical use.

Perioperative Strategies Are Redefining Curative Pathways in Biliary Tract Cancer Nature Reviews Clinical Oncology | March 2026

Introduction Biliary tract cancers (BTCs), including intrahepatic, perihilar and distal cholangiocarcinoma as well as gallbladder cancer, remain among the most aggressive gastrointestinal malignancies. Curative treatment has traditionally relied on surgical resection, yet most patients present with advanced disease, limiting operability. Even after complete resection, recurrence is common, underscoring the need for more effective perioperative strategies to improve long-term outcomes. Problem Statement Management of BTC in the perioperative setting remains challenging owing to disease heterogeneity, frequent late-stage presentation, and high postoperative recurrence rates. While surgery remains the only established curative option, its benefit is limited by strict resectability criteria and poor long-term disease control. The central challenge is how to safely expand curative-intent treatment through better patient selection, integration of systemic and locoregional therapies, and refinement of transplantation strategies. Summary This review outlines the evolving perioperative landscape in BTC, emphasizing a shift from surgery alone toward a more integrated, multidisciplinary treatment model. Surgical resection remains the cornerstone of curative therapy, with adjuvant capecitabine continuing as the current standard after resection. However, increasing emphasis is being placed on neoadjuvant strategies to improve resectability and optimize oncologic outcomes. Liver transplantation is emerging as a promising curative option in highly selected patients with unresectable perihilar or intrahepatic cholangiocarcinoma, particularly when paired with neoadjuvant therapy and rigorous selection criteria. The review also highlights the growing relevance of immune-checkpoint inhibitors and targeted therapies, which have shown benefit in advanced disease and are now being explored in earlier-stage and perioperative settings. Importantly, earlier molecular profiling may refine prognostication and enable biomarker-guided treatment selection before surgery. Overall, perioperative BTC management is moving toward precision-based, individualized care, where multimodal therapy and biologic stratification are expected to play a central role in expanding curative opportunities.

Refining Classification and Prognosis of Gastric Neuroendocrine Neoplasms: Virchows Archiv | November 2025

Introduction Gastric neuroendocrine neoplasms (gNENs) represent a heterogeneous group of tumors with rising incidence, encompassing well-differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs). Accurate classification is critical, as clinical behavior ranges from indolent lesions amenable to endoscopic surveillance to aggressive malignancies requiring multimodal therapy. Recent advances emphasize the integration of histopathology with clinical and biochemical parameters, particularly in gastric NETs. Problem Statement Traditional classification based solely on proliferative indices (mitotic count and Ki-67) is insufficient in gastric NETs, where tumor biology is strongly influenced by the underlying clinicopathologic context. There is a need for a more practical and prognostically relevant framework that incorporates factors such as gastrin levels, gastric acid secretion, and background mucosal pathology to guide diagnosis and management. Summary This comprehensive review highlights that gNENs are classified into NETs, NECs, and MiNENs, with distinct biological and clinical profiles. Among these, enterochromaffin-like (ECL) cell NETs are most common and uniquely stratified into five subtypes based on pathogenetic mechanisms, including hypergastrinemia and acid secretion status. Type 1 NETs, associated with autoimmune atrophic gastritis, are typically indolent with excellent prognosis, whereas type 3 NETs arise sporadically and demonstrate aggressive behavior with higher metastatic potential. Intermediate forms, such as type 2 NETs linked to MEN1-associated gastrinoma, require targeted evaluation and management. Importantly, the review proposes a simplified, clinically applicable classification based on gastrin levels and gastric acid status, enabling rapid risk stratification and treatment decisions. NECs and MiNENs remain highly aggressive entities with poor prognosis, necessitating early recognition and intensive therapy. Overall, integrating morphologic, immunophenotypic, and clinical data is essential for accurate diagnosis, prognostication, and personalized management of gastric neuroendocrine neoplasms.

KRAS Inhibition in Oncology: Precision Oncology | April 2026

Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options. However, clinical responses have been highly variable across different tumor types, raising important questions about how best to use these therapies in precision oncology. Problem Statement KRAS mutation status alone is insufficient to predict response to KRAS-targeted therapies, limiting their effectiveness when applied without broader biological context. Summary This perspective highlights a fundamental shift in oncology thinking: mutation is not enough—context defines response. Although KRAS inhibitors represent a major therapeutic advance, their inconsistent efficacy across cancers underscores the complexity of tumor biology. The article proposes a multidimensional framework that integrates several critical layers beyond KRAS mutation status. These include the tissue of origin, co-existing genetic alterations, downstream signaling pathways, and the tumor immune microenvironment. Together, these factors influence how tumors respond to KRAS inhibition. The key implication is that precision oncology must evolve from a single-mutation approach to a context-driven strategy. This has direct relevance for clinical practice and research, including better patient selection, improved biomarker development, and more rational clinical trial design. Ultimately, the paper emphasizes that the future of targeted therapy lies not just in identifying mutations, but in understanding the biological ecosystem in which those mutations operate.

Daraxonrasib in First-Line mPDAC: Cancer Research | April 2026

Introduction Metastatic pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with a 5-year survival of approximately 3%. Current first-line chemotherapy offers limited benefit and significant toxicity. Given that over 90% of PDAC cases harbor RAS mutations, targeting this pathway has long been a major therapeutic goal. Daraxonrasib is a novel oral agent designed to inhibit active RAS across multiple mutations, offering a potentially transformative approach. Problem Statement Effective and tolerable first-line targeted therapies for RAS-mutant pancreatic cancer are lacking, despite the central role of RAS in disease biology. Summary This early-phase study evaluates daraxonrasib as first-line monotherapy in RAS-mutant mPDAC and demonstrates encouraging preliminary results. The treatment showed a manageable safety profile, with common adverse effects including rash, diarrhea, and mucositis, but importantly no grade 4 or 5 toxicities. Although dose modifications were frequent, treatment discontinuation was rare. Efficacy signals are particularly noteworthy. Objective response rates approached 50%, with disease control rates exceeding 90%, which compares favorably to standard chemotherapy benchmarks. Additionally, progression-free survival at 6 months was 71%, and overall survival at 6 months reached 83%, suggesting meaningful clinical activity. A key strength of the study is the incorporation of circulating tumor DNA (ctDNA) analysis, where all evaluable patients demonstrated significant reduction in RAS mutation burden, and more than half achieved complete clearance—supporting a strong biological effect. Overall, daraxonrasib represents a promising targeted strategy in a historically treatment-resistant disease. These findings justify ongoing phase 3 trials and signal a potential shift toward molecularly driven first-line therapy in pancreatic cancer.

KRAS Inhibition in Oncology: Precision Oncology | April 2026

Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options. However, clinical responses have been highly variable across different tumor types, raising important questions about how best to use these therapies in precision oncology. Problem Statement KRAS mutation status alone is insufficient to predict response to KRAS-targeted therapies, limiting their effectiveness when applied without broader biological context. Summary This perspective highlights a fundamental shift in oncology thinking: mutation is not enough—context defines response. Although KRAS inhibitors represent a major therapeutic advance, their inconsistent efficacy across cancers underscores the complexity of tumor biology. The article proposes a multidimensional framework that integrates several critical layers beyond KRAS mutation status. These include the tissue of origin, co-existing genetic alterations, downstream signaling pathways, and the tumor immune microenvironment. Together, these factors influence how tumors respond to KRAS inhibition. The key implication is that precision oncology must evolve from a single-mutation approach to a context-driven strategy. This has direct relevance for clinical practice and research, including better patient selection, improved biomarker development, and more rational clinical trial design. Ultimately, the paper emphasizes that the future of targeted therapy lies not just in identifying mutations, but in understanding the biological ecosystem in which those mutations operate.